SYRE - Company ID 0001636282
Spyre Therapeutics, Inc. (SYRE) reported net income of -$155.20M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$155.20M | +25.4% |
| FY 2024 | -$208.02M | +38.6% |
| FY 2023 | -$338.79M | -304.2% |
| FY 2022 | -$83.81M | -27.4% |
| FY 2021 | -$65.80M | +18.7% |
| FY 2020 | -$80.89M | -3.4% |
| FY 2019 | -$78.25M | -76.5% |
| FY 2018 | -$44.35M | -62.8% |
| FY 2017 |
Spyre Therapeutics, Inc. (SYRE) reported net income of -$155.20M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2014 and fiscal 2025, Spyre Therapeutics, Inc.'s net income declined from -$10.35M to -$155.20M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$27.24M |
| -25.5% |
| FY 2016 | -$21.70M | -92.1% |
| FY 2015 | -$11.29M | -9.2% |
| FY 2014 | -$10.35M | - |